Skip to content

Pilot Randomized Controlled Trial of Telemedicine for Individuals With Parkinson Disease in a Rural Population

Pilot Randomized Controlled Trial of Telemedicine for Individuals With Parkinson Disease in a Rural Population

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00668551
Acronym
Tele-PD
Enrollment
14
Registered
2008-04-29
Start date
2008-04-30
Completion date
2008-11-30
Last updated
2009-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson disease, Telemedicine

Brief summary

To eliminate barriers (such as travel and cost) to specialized Parkinson disease (PD) care, two movement disorder specialists at the University of Rochester will be providing telemedicine visits for patients with PD who reside in the Presbyterian Home for Central New York in New Hartford, NY, or for individuals who participate in the local support group that meets at the nursing home. Participants will attend 3 telemedicine visits at the Presbyterian Home over the course of 6 months. We hypothesize that this telemedicine model will in time improve access to care and hence the quality of life and quality of care of individuals with PD.

Detailed description

Study participants are recruited from the Presbyterian Home and from the Central New York Parkinson Support Group. Anyone interested will attend a screening and baseline visit at the Presbyterian Home, where they will receive baseline surveys and a motor assessment. Eligible participants will be randomized to receive either telemedicine or standard of care. Each telemedicine visit (Month 1, Month 3, Month 6) will take place in a 1:1 fashion between the study participant and the physician investigator - one of two movement disorder specialists from the University of Rochester - via televideo linkage, and will last approximately 30-60 minutes. The study participant will be observed by the physician investigator and she/he will be accompanied by a Presbyterian Home staff member to ensure safety throughout the telemedicine visit. The visit will be structured much the same as a standard clinical visit and will include: * Study participant's update on his or her clinical condition * Review of current medications, which will be provided in advance of the visit * Review and update of medical and social histories * Vital signs, including weight (provided by the Presbyterian Home staff) * Pertinent neurological exam, including a modified motor examination led by physician investigator * Assessment of current clinical state * Dictated recommendations including a letter to the attending physician for ongoing clinical care, including changes to the PD medications Participants assigned to the control group will receive their care as routinely scheduled with their own primary care physician and/or neurologist. Staff members from the University of Rochester will return to the Presbyterian Home within one month of the six month study to complete final assessments with all study participants. These will include: * Reportable events form * Health care events form * Quality of life and healthcare evaluation surveys * Continuation of care survey * 1:1 interviews * Telemedicine focus groups

Interventions

None listed

Sponsors

Presbyterian Homes & Services
CollaboratorOTHER
University of Rochester
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Willing and able to provide informed consent * Age 30 years old or older * Clinical diagnosis of idiopathic Parkinson's disease as determined by having two of the four cardinal features of PD (rest tremor, bradykinesia, cogwheel rigidity, and gait instability) and no better alternative explanation for the etiology of the symptoms * Able to converse in English * Willing and able to complete study requirements

Exclusion criteria

* Any neurological, medical, or psychiatric condition that would preclude the patient having the ability to provide informed consent or to participate in the telemedicine visit.

Design outcomes

Primary

MeasureTime frame
The feasibility of telemedicine, based on participant ability to complete 75% or more of the trial visits.6 months

Secondary

MeasureTime frame
Parkinson's Disease Questionnaire-39 (PDQ-39)6 months
EuroQol (EQ-5D)6 months
Geriatric Depression Scale Short Form (GDS-15)6 months
Qualitative assessment, including a telemedicine focus group and 1:1 interviews with study participants6 months
Modified Group Health Association of America's Consumer Satisfaction Survey (GHAA)6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026